New cancer collaborations
Enlarge image


New cancer collaborations

30.01.2013 - Swiss 4-Antibody and Ludwig Institute will expand their cooperation, while Curie-Cancer and Genosplice Technology inked a cancer genomics pact.

The two new cancer collaborations were kicked-off yesterday. The French bioinformatics expert Genosplice Technology and the tech-transfer arm of Paris-based Institut Curie aim at developing high value-added cancer genomic approaches. GenoSplice will gain access to several Curie-Cancer technology platforms and research programmes and will contribute to the development of new products against cancer through genome mapping using its bioinformatics expertise. The partners aim to define a genomic map for prostate cancer including pathways and therapeutic options. In a second project the French will seek response biomarkers for a preclinical peptide that already has been proven effective in mouse xenograft experiments. 

On the same day, Swiss 4-Antibody AG and US-based Ludwig Institute expanded its existing cancer antibody development pact with three new targets provided by Brazilian antibody developer Recepta Biopharma SA. The partners will focus their R&D partnership on the generation of three antibodies targeting important cancer immune checkpoints. Under the terms of the agreement, 4-Antibody will use its high-throughput Retrocyte Display® technology platform to generate and produce fully human therapeutic antibody candidates. The Ludwig Institute will validate the new constructs and then, together with Recepta Biopharma, will take these antibody drugs into early clinical testing from 2015 in the US and Brazil.  

4-Antibody and Ludwig jointly will own the antibody drugs while Recepta Biopharma has baged exclusive commercial rights to Brazil in return for undisclosed licensing fees. 4-Antibody will take the lead securing commercialisation partners for the antibody drugs in territories outside Brazil on behalf of itself and Ludwig. Future returns from the collaboration outside of Brazil will be shared among the three parties.



26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • DIAMYD MEDICAL -B- (S)10.00 SEK14.29%
  • SERODUS (N)2.67 NOK9.43%


  • EVOCUTIS (UK)0.09 GBP-10.00%
  • VERONA PHARMA (UK)3.05 GBP-6.15%
  • SAREUM HOLDINGS (UK)0.19 GBP-5.00%


  • PLETHORA (UK)5.62 GBP80.1%
  • PROTHENA PLC (IE)73.19 USD46.1%
  • CELLECTIS (F)30.70 EUR32.8%


  • EPIGENOMICS (D)1.87 EUR-58.6%
  • EVOCUTIS (UK)0.09 GBP-40.0%


  • KARO BIO (S)38.10 SEK5266.2%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)45.70 EUR255.9%


  • BIOTEST (D)15.34 EUR-81.0%
  • EVOCUTIS (UK)0.09 GBP-78.6%

No liability assumed, Date: 25.11.2015